3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Bevacizumab
21
Paclitaxel
19
Carboplatin
15
pembrolizumab
14
Specimen Handling
14
liposomal doxorubicin
12
Magnetic Resonance Spectroscopy
12
Cyclophosphamide
11
olaparib
10
Gemcitabine
10
fludarabine
9
Topotecan
8
Biopsy
8
Fulvestrant
7
niraparib
6
Nivolumab
6
palbociclib
5
Taxes
5
Immunoglobulin G
5
Doxorubicin
5
Disulfides
5
aldesleukin
4
trastuzumab deruxtecan
3
mirvetuximab soravtansine
3
binimetinib
3
Oxaliplatin
3
Cisplatin
3
AZD5305
3
1-dodecylpyridoxal
3
ulixertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Histamine Antagonists
×
30 days
×
Clear all
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled